Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 250,000 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $70.36, for a total transaction of $17,590,000.00. Following the transaction, the chief executive officer owned 50,000 shares of the company’s stock, valued at $3,518,000. The trade was a 83.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 1.6%

Tempus AI stock opened at $77.84 on Friday. The company has a market cap of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.54. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $91.83. The company has a fifty day simple moving average of $70.58 and a 200 day simple moving average of $57.05. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the firm posted ($0.22) EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. Research analysts anticipate that Tempus AI, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Large investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new position in shares of Tempus AI during the 3rd quarter worth about $27,000. EMC Capital Management bought a new stake in shares of Tempus AI in the 2nd quarter valued at about $29,000. Whittier Trust Co. lifted its stake in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the last quarter. Ulland Investment Advisors LLC acquired a new stake in Tempus AI in the 3rd quarter valued at about $41,000. Finally, Global Assets Advisory LLC acquired a new stake in Tempus AI in the 1st quarter valued at about $46,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on TEM. Rothschild & Co Redburn started coverage on Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research report on Monday. JPMorgan Chase & Co. raised their price target on Tempus AI from $45.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 14th. HC Wainwright boosted their price target on Tempus AI from $66.00 to $68.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $76.00 in a research note on Tuesday, September 1st. Eleven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Tempus AI currently has an average rating of “Hold” and an average target price of $72.47.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.